BRIEF — Surgical Innovations Says Trading In The First Half Of The Year Was Broadly Flat

Sept 30 (Reuters) — Surgical Innovations Group PLC: Surgical Innovations:us Sales Now Normalised Following Warehouse Transition, But Shortfall Incurred During H1 Not Expected To Be Recovered During 2026 (Adds Dropped Word 'Us') Surgical Innovations: Tariff-related Impact On Market Opportunities Expected To Remain Headwind In H2, May Continue To Constrain Us Growth In Near Term (Adds Dropped Word 'Us') Surgical Innovations H1 Adjusted Ebitda Gbp 33 Thousand Surgical Innovations H1 Gross Profit Gbp 1.748 Million Surgical Innovations H1 Revenue Gbp 6.019 Million Surgical Innovations H1 Ebit Gbp -230 Thousand Surgical Innovations Group: Trading Headwinds Experienced In H1 Are Expected To Persist In Certain Markets, Most Notably The United States Surgical Innovations Group: Has Adequate Cash Resources And Invoice Financing Facility To Continue To Operate For The Foreseeable Future Surgical Innovations: Expect Some External Headwinds, Particularly Us Tariffs, To Persist During H2, Though Remain Confident In Outlook For Business Surgical Innovations: Trading In The First Half Of The Year Was Broadly Flat Surgical Innovations: Actively Exploring Additional Routes To Market And.